voriconazole / Generic mfg. - LARVOL DELTA

PHASE 1/2 STUDY OF THE ALL-ORAL COMBINATION OF REVUMENIB (SNDX-5613) WITH DECITABINE/CEDAZURIDINE (ASTX727) AND VENETOCLAX (SAVE) IN RELAPSED/REFRACTORY AML (EHA 2026) - P1/2 | "ASTX727 (35/100 mg) was given PO on days 1–5, venetoclax 400 mg PO on days 1–14, and revumenib 113 mg (DL0) or 163 mg (DL1) PO Q12h on days 1–28 with posaconazole or voriconazole prophylaxis. Summary/Conclusion The all-oral combination of revumenib , venetoclax, and decitabine y ields high remission rates in R/R AML with KMT2Ar , NPM1mt , or NUP98r , with durable responses in patients achieving deep remission. Fig.1: Duration of response by genotype"

IO biomarker • P1/2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Respiratory Diseases • Thrombocytopenia • BCL2 • KMT2A • NUP98

Risk stratification of ibrutinib toxicity co-administered with triazole antifungals: insights from real-world pharmacovigilance and clinical evidence. (PubMed, Front Med (Lausanne)) - "Voriconazole-containing reports showed a signal for cerebral aspergillosis (ROR = 474.61, n = 3), posaconazole-containing reports showed cardiac events including pericardial effusion (ROR = 24.95, n = 4), and isavuconazole-containing reports showed a signal for febrile neutropenia (ROR = 29.7, n = 4). The identified pharmacovigilance signals are clinically interpretable in light of known CYP3A-mediated pharmacokinetic interactions, but they should be considered hypothesis-generating rather than causal. These findings support clinical awareness, individualized medication review, and further validation in studies with defined denominators and appropriate control of confounding."

Adverse events • Journal • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Neutropenia • Pulmonary Disease • Respiratory Diseases

Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy (clinicaltrials.gov) - P4 | N=24 | Completed | Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

New P4 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) (ASH 2023) - P1/2 | "ASTX727 (decitabine/ cedazuridine) was administered at 35 mg/100 mg PO daily days 1-5, venetoclax at 400 mg (target dose) PO daily days 1-14, and revumenib 113 mg PO Q12h (dose level [DL] 0) or 163 mg PO Q12h (DL 1, used in phase II monotherapy), days 1-28 with either posaconazole or voriconazole (strong CYP3A4 inhibitors, for antifungal prophylaxis). Early results indicate acceptable safety and high efficacy of this combination in R/R myeloid leukemias with either KMT2Ar or NPM1mt or NUP98r. This study is ongoing with plans to establish the recommended phase 2 dose and optimize delivery of this combination."

IO biomarker • P1/2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Neutropenia • Oncology • Pain • Renal Disease • Thrombocytopenia • Transplantation • KMT2A • NPM1 • NUP98

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML (ASH 2024) - P1/2 | "ASTX727 (decitabine/ cedazuridine) was administered at 35 mg/100 mg PO daily days 1-5, venetoclax at 400 mg (target dose) PO daily days 1-14, and revumenib 113 mg PO Q12h (dose level [DL] 0) or 163 mg PO Q12h (DL 1, used in phase II monotherapy), days 1-28 with either posaconazole or voriconazole (strong CYP3A4 inhibitors). Conclusions : The all-oral combination SAVE results in high rates of remission in pts with R/R AML with KMT2Ar, NPM1mt or NUP98r. In addition to the R/R cohort, a frontline cohort is now enrolling pts."

IO biomarker • P1/2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Metabolic Disorders • Nephrology • Neutropenia • Oncology • Renal Disease • Respiratory Diseases • Thrombocytopenia • KMT2A • NPM1 • NUP98

A high-throughput LC-MS/MS assay for therapeutic drug monitoring of combined immunosuppressive and antimicrobial therapy. (PubMed, J Chromatogr B Analyt Technol Biomed Life Sci) - "The specific SRM transition of 13C₂,d₄-cyclosporine A was characterized for the first time, and a robust LC-MS/MS method was established for the simultaneous quantification of the six target drugs in human whole blood."

Journal

Opportunistic Quambalaria fungal endophthalmitis in fumarate-treated multiple sclerosis complicated by multifocal postinfectious cerebral vasculopathy. (PubMed, Retin Cases Brief Rep) - "Quambalaria is an exceptionally rare ocular pathogen that can cause aggressive endophthalmitis. . Vitrectomy and intensive intravitreal voriconazole arrested an infection that had progressed despite treatment; the globe was preserved, although final visual acuity was light perception."

Journal • CNS Disorders • Dermatology • Infectious Disease • Inflammation • Multiple Sclerosis • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis

In vitro activity profiles and temporal trends in reduced susceptibility to azoles in Coccidioides in the United States. (PubMed, Antimicrob Agents Chemother) - "Isavuconazole MIC parameters were available during the second period and similar to those of voriconazole. Fluctuations in GM MICs and the percentage of isolates with elevated MICs were observed with fluconazole, itraconazole, and posaconazole, with elevated values observed between 2011 and 2019. Continued surveillance is needed, and outcome data are required to determine if the consistently reduced susceptibility observed with fluconazole or in those infected with strains that have higher MICs results in poorer outcomes in patients with coccidioidomycosis."

Journal • Preclinical • Dermatology • Respiratory Diseases

A trial of amphotericin B or voriconazole followed by oral triazoles for non-HIV-associated talaromycosis in South China (ERS 2026) - " In this prospective controlled trial, we randomly assigned 98 HIV-negative adults with talaromycosis to receive either intravenous amphotericin B/amphotericin B liposomes or intravenous voriconazole as initial induction therapy, followed by maintenance treatment with oral voriconazole or itraconazole, with a total treatment course not less than 36 weeks. Amphotericin B and voriconazole had similar clinical resolution times and cure rates in the treatment of HIV-negative talaromycosis. voriconazole was associated with a lower risk of severe laboratory adverse events."

Cough • Infectious Disease • Respiratory Diseases

Culture-Proven Haemophilus influenzae Endophthalmitis After Intravitreal Topotecan for Retinoblastoma. (PubMed, J Vitreoretin Dis) - "Urgent 23-gauge pars plana vitrectomy was performed to clear dense vitritis and maintain oncologic control using a closed-system approach, melphalan irrigation (5 µg/mL), IVT topotecan, port-site cryotherapy, and silicone oil tamponade. The patient also received IVT vancomycin, ceftazidime, and voriconazole...The infection resolved, the tumor continued to regress, and no extraocular tumor spread was observed during 24 months of follow-up. Early, tailored vitrectomy may help preserve vision in severe endophthalmitis after IVT chemotherapy for retinoblastoma when strict oncologic precautions are maintained, with long-term follow-up required to monitor for tumor recurrence or extraocular spread."

Journal • Eye Cancer • Infectious Disease • Influenza • Ocular Infections • Ocular Inflammation • Ocular Melanoma • Oncology • Ophthalmology • Respiratory Diseases • Retinal Disorders • Retinoblastoma • Solid Tumor

Rapid Antifungal Susceptibility Classification of Aspergillus Species Using AI-Assisted Analysis of Routine MALDI-TOF MS Spectra: A Proof-of-Concept Study. (PubMed, Ann Lab Med) - "Their performance in predicting susceptibility to four antifungal agents (voriconazole, posaconazole, itraconazole, and amphotericin B) was evaluated using a validation set comprising A. flavus (N=24), A. fumigatus (N=24), and A. lentulus (N=22), based on categorical agreement (CA), very major error (VME), major error (ME), sensitivity, and specificity. However, its clinical performance across species-antifungal agent combinations was limited. Further optimization, evaluation with larger multicenter datasets, and external validation are required before considering clinical adoption."

Journal

Assessing the Frequency, Type, and Severity of Drug-Induced Liver Injury with Azole Antifungal Drugs for Dermatophytosis. (PubMed, J Coll Physicians Surg Pak) - "This study strengthens the association of azole antifungals with mild biochemical liver abnormalities and infrequent DILI. A short- term course of azoles causes a rise in ALP and AST, while longer courses cause a more comprehensive rise in LFTs. Thus, this highlights a time-dependent effect and necessitates regular monitoring of LFTs during and after treatment."

Journal • Cholestasis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hepatology • Infectious Disease • Liver Failure

Dematiaceous fungal keratitis: prevalence, spectrum, clinical features, outcome, and antifungal susceptibility from a tertiary care centre in North India. (PubMed, Med Mycol) - "Antifungal susceptibility testing (AFST) was performed as per the CLSI (Clinical Laboratory and Standards Institute) broth microdilution method (M38-A2) for a panel of 9 drugs including voriconazole, itraconazole, posaconazole, luliconazole, miconazole, ketoconazole, amphotericin-B, natamycin and terbinafine. as the predominant causative agent. In vitro susceptibility of voriconazole demonstrated better performance against DFK isolates."

Journal • Infectious Disease • Keratitis • Ocular Inflammation • Ophthalmology

Molecular characterization and antifungal susceptibility of Aspergillus spp. isolated from critically ill COVID-19 patients: implications for suspected COVID-19-associated pulmonary aspergillosis (CAPA) in a Brazilian tertiary referral hospital. (PubMed, Med Mycol) - "Susceptibility to amphotericin B (AMB), itraconazole (ITZ), voriconazole (VCZ), and posaconazole (PCZ) was determined according to CLSI M38-A2, and cyp51A and its promoter were analyzed in A. fumigatus. Silent cyp51A mutations occurred in three A. fumigatus isolates, while several section Flavi isolates displayed multiazole NWT. These findings highlight diagnostic limitations and emerging azole resistance, supporting susceptibility testing and surveillance."

Journal • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Clinical characteristics, susceptibility profiles, and outcomes of infection with Alternaria species: a 14-year retrospective study. (PubMed, Med Mycol) - "Posaconazole and itraconazole demonstrated low MICs (MIC₅₀/MIC₉₀: 0.06/0.5 and 0.25/0.5 µg/mL, respectively). Voriconazole and isavuconazole showed higher MIC₅₀/MIC₉₀ (1/2 and 2/4 µg/mL)...Interpretive criteria for Alternaria spp. are needed to guide empiric and definitive therapy."

Journal • Retrospective data • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Oncology • Solid Organ Transplantation • Transplantation

Comparative efficacy of Voriconazole versus High-Dose Terbinafine in Recalcitrant Tinea Corporis and Cruris. (EADV 2026) - No abstract available

Clinical • Dermatology

Coinfection of Pneumocystis jirovecii and Aspergillus fumigatus in the lung: A case report. (PubMed, Medicine (Baltimore)) - "bronchoalveolar lavage combined with metagenomic next-generation sequencing enables rapid diagnosis of concurrent opportunistic pulmonary infections. Paradoxical radiographic worsening despite clinical improvement may suggest an immune reconstitution inflammatory syndrome-like inflammatory response, although persistent or progressive infection cannot be excluded."

Journal • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Oncology • Respiratory Diseases

Trichosporon austroamericanum Infection After Kidney Transplantation: A Six Case Series Revealing a Newly Recognized Pathogen with Allograft Tropism. (PubMed, Kidney360) - "These cases highlight the pathogenic potential of T. austroamericanum, presenting as KT site infection, with possible allograft infiltration. Management should include early antifungal therapy-voriconazole as first-line for at least 4 weeks-combined with surgical debridement, and if possible, immunosuppression reduction."

Journal • Fibrosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Septic Shock • Solid Organ Transplantation • Transplantation

Clinical Analysis of Otitis Externa Caused by Multidrug-Resistant Fungus Candida auris (AAO-HNSF 2026) - "Antifungal susceptibility testing for fluconazole, voriconazole, amphotericin B, and echinocandins was conducted following CLSI guidelines... C. auris OE requires heightened clinical vigilance due to high resistance and recurrence rates. Although the East Asian clade remains predominant in Korea, the increasing emergence of the virulent South Asian clade necessitates the use of molecular diagnostics like MALDI-TOF MS. Personalized, susceptibility-guided antifungal therapy is essential for effective management and the prevention of nosocomial transmission."

Clinical • Diabetes • Infectious Disease • Metabolic Disorders • Otorhinolaryngology • Pruritus

Repeated voriconazole therapeutic drug monitoring in hospitalised patients: a real-world cohort study of out-of-range exposure and concentration response to dose adjustment. (PubMed, Front Pharmacol) - "In the 445-episode complete-case models, subtherapeutic exposure was associated with rifampin-like inducer co-administration (OR 16.48, 95% CrI 2.38-139.44) and lower daily dose (OR 0.45 per 100 mg, 95% CrI 0.29-0.66), whereas supratherapeutic exposure was associated with the CYP2C19 poor-metaboliser phenotype (OR 5.24, 95% CrI 1.76-16.66), higher log-CRP (OR 1.69, 95% CrI 1.23-2.40), and higher total bilirubin (OR 1.09 per 10 μmol/L, 95% CrI 1.03-1.15). After dose reduction, supratherapeutic concentrations frequently did not return to range; this descriptive pattern is compatible with several contributors, including resampling before a new steady state and voriconazole's nonlinear metabolism. These findings may help clinicians interpret repeated TDM results in complex inpatient settings."

Journal • Real-world evidence • Inflammation • CYP2C19

When Voriconazole Fails: Practical Management of Azole-Resistant Aspergillus – Chest Infections Section (CHEST 2026) - No abstract available

Infectious Disease

7801: When Voriconazole Fails: Practical Management of Azole-Resistant Aspergillus - Chest Infections Section (CHEST 2026) - "This interactive, case-based session will review the epidemiology and mechanisms of azole resistance, highlight clinical scenarios in which resistance should be suspected, and discuss practical approaches to diagnosis and management. The speaker will emphasize real-world decision-making relevant to pulmonologists, intensivists, and clinicians caring for patients with invasive and chronic pulmonary aspergillosis."

Infectious Disease • Pulmonary Disease • Respiratory Diseases

The triple threat: Managing concomitant bacterial, viral and fungal infections in a recent renal transplant recipient (TTS 2026) - "He received Antithymocyte globulin induction followed by maintenance immunosuppression with prednisolone, tacrolimus, and mycophenolate mofetil...Figure 1: FDG PET scan showing multiple hypermetabolic lymph nodes Figure 2 : H&E stain of lymph node biopsy showing growing hyphae In view of multiple infective complications, our patient was treated with injectable gancyclovir, antitubercular drugs and oral voriconazole.Doses of immunosuppressant drugs were adjusted... Learnings from this case: Careful follow-up of posttransplant recipients is vital, with therapeutic drug monitoring in addition to assessment of immunological and infectious risk stratification. A high index of suspicion of concomitant infections should be present. This case taught us how to manage three major infections while balancing immunosuppression, antibiotics, and graft function that we see in the day-to-day practice of transplant clinics."

Clinical • Chronic Kidney Disease • Cough • Cytomegalovirus Infection • Dengue Fever • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Leukopenia • Nephrology • Respiratory Diseases • Transplantation • Tuberculosis

WHEN IMPROVEMENT MISLEADS: PULMONARY MUCORMYCOSIS MASQUERADING AS VORICONAZOLE-RESPONSIVE ASPERGILLOSIS IN PROLONGED NEUTROPENIA (CHEST 2026) - No abstract available

Hematological Disorders • Infectious Disease • Neutropenia • Respiratory Diseases

A DANGEROUS DIP: SEVERE HYPOGLYCEMIA AFTER INITIATION OF ORAL VORICONAZOLE THERAPY (CHEST 2026) - No abstract available

Severe Hypoglycemia